About PyrAmes & Our Technology
Our Platforms
Presenting Boppli™
Accurate1, non-invasive, continuous, wireless BP monitoring for neonatal and pediatric patients.
Learn More
cNIBP Health Impact
PyrAmes platforms will provide options to continuously monitor blood pressure cNIBP for patients of all ages.
Over 50% of NICU Admissions
could benefit from BP monitoring but would not receive an arterial line because it is invasive and costly.2
50% of Adults have High BP
50% of adults are affected by high blood pressure in the US, increasing their mortality rates.3
7.6 Million Deaths Annually
Raised blood pressure (BP) is responsible for 7.6 million deaths worldwide annually.4
cNIBP & Early Detection
cNIBP has the potential for early detection of conditions within preterm infants and adults.
News & Updates
February 10, 2022
PyrAmes selected for LG NOVA’s Mission for the Future global challenge “First 50”
Global Challenge
PyrAmes chosen from 1,300+ applicants to collaborate with LG on innovative connected health products.
CUPERTINO, CA, February 10, 2022 -- PyrAmes, Inc., a digital healthcare company focused on innovative products for continuous blood pressure monitoring, today announced its selection by the LG Electronics North American Innovation Center, LG NOVA in its inaugural cohort of startups selected in its large-scale Mission for the Future global challenge competition. Chosen from a group of over 1,300 applicants, the “First 50” companies represent new developments in several areas including Connected Health, and will work with the LG NOVA team on their business concepts.
(more…)
January 17, 2022
PyrAmes Technology Featured in Neonatal Intensive Care Journal
PyrAmes Technology
The PyrAmes Boppli™ device is featured on page 11 in the Winter 2022 edition of Neonatal Intensive Care: The Journal of Perinatology-Neonatology. The article focuses on how the Boppli is being developed to meet the need for continuous, non-invasive blood pressure monitoring in the neonatal intensive care unit (NICU).December 1, 2021
PyrAmes selected for Plug and Play Japan’s Winter/Spring 2022 Batch Accelerator Program
Accelerator Program
Plug and Play Japan and its 49 corporate partners have selected PyrAmes for its global accelerator program, including 67 companies from Japan, the U.S., Canada, India, the United Kingdom, Spain, and more. PyrAmes receives business development resources in the program’s Health track, focusing on Plug and Play’s interest in sensors and wearables. Plug and Play Japan is a subsidiary of Plug and Play; a global innovation platform headquartered in Silicon Valley. Its major strength is to provide consortium-type programs with its extensive global network.
2020 FDA Breakthrough Device Designation
Founding Member of CDC National Hypertension Control Roundtable
2020 SWPDC Pediatric Device Award, Member of SWPDC
2019 MedTech Innovator Accelerator & 2020 NCC-PDI MedTech Innovator Pediatric Accelerator
Exponential Medicine 2019 One to Watch Award